Diverse inhibitor chemotypes targeting Trypanosoma cruzi CYP51

PLoS Neglected Tropical Diseases

Volumn 6, Issue 7, 2012, Pages

  Gunatilleke, Shamila S ^a,b   Calvet, Claudia M ^a,c   Johnston, Jonathan B ^a   Chen, Chiung Kuang ^a   Erenburg, Grigori ^d   Gut, Jiri ^a,b   Engel, Juan C ^a,b   Ang, Kenny K H ^a   Mulvaney, Joseph ^a   Chen, Steven ^a   Arkin, Michelle R ^a   McKerrow, James H ^a,b   Podust, Larissa M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

STEROL 14ALPHA DEMETHYLASE; STEROL 14ALPHA DEMETHYLASE INHIBITOR; ANTIPROTOZOAL AGENT; CYP51 PROTEIN, TRYPANOSOMA CRUZI; CYTOCHROME P450;

AMASTIGOTE; ANIMAL CELL; ARTICLE; CHAGAS DISEASE; CONTROLLED STUDY; COW; HIGH THROUGHPUT SCREENING; LIBRARY; LIPID ANALYSIS; MASS FRAGMENTOGRAPHY; MOUSE; MYOBLAST; NONHUMAN; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION; TRYPANOSOMA CRUZI; CHEMISTRY; DRUG ANTAGONISM; DRUG SCREENING; DRUG SENSITIVITY; ISOLATION AND PURIFICATION; METHODOLOGY; MOLECULAR DYNAMICS;

ANTIPROTOZOAL AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG EVALUATION, PRECLINICAL; HIGH-THROUGHPUT SCREENING ASSAYS; MOLECULAR DYNAMICS SIMULATION; PARASITIC SENSITIVITY TESTS;

EID: 84864612078     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001736     Document Type: Article

References (63)

1. Chagas C, ((1909)) Nova trypanozomiaze humana: estudos sobre a morfolojia e o ciclo evolutivo do Schizotrypanum cruzi n. gen., n. sp., ajente etiolojico de nova entidade morbida do homem. Mem Inst Oswaldo Cruz 1:: 159--218.
2. Maya JD, Cassels BK, Iturriaga-Vasquez P, Ferreira J, Faundez M, et al. ((2007)) Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host. Comp Biochem Physiol, Part A Mol Integr Physiol 146:: 601--620.
3. Rassi A Jr, Rassi A, Marin-Neto JA, ((2010)) Chagas disease. Lancet 375:: 1388--1402.
4. Buckner FS, Navabi N, ((2010)) Advances in Chagas disease drug development: 2009-2010. Curr Opin Infect Dis 23:: 609--616.
5. Liendo A, Visbal G, Piras MM, Piras R, Urbina JA, ((1999)) Sterol composition and biosynthesis in Trypanosoma cruzi amastigotes. Mol Biochem Parasitol 104:: 81--91.
6. Roberts CW, McLeod R, Rice DW, Ginger M, Chance ML, et al. ((2003)) Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa. Mol Biochem Parasitol 126:: 129--142.
7. de Souza W, Rodrigues JC, ((2009)) Sterol biosynthesis pathway as target for anti-trypanosomatid drugs. Interdiscip Perspect Infect Dis 2009:: 642502.
8. Buckner F (2008) Sterol 14-demethylase inhibitors for Trypanosoma cruzi infections. In: Drug Targets in Kinetoplastid Parasites. Majumder HK, editor. New York: Springer. 61-80.
9. Ferraz ML, Gazzinelli RT, Alves RO, Urbina JA, Romanha AJ, ((2007)) The anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole. Antimicrob Agents Chemother 51:: 1359--1364.
10. Urbina JA, ((2009)) Ergosterol biosynthesis and drug development for Chagas disease. Mem Inst Oswaldo Cruz 104 Suppl 1:: 311--318.
11. Olivieri BP, Molina JT, de Castro SL, Pereira MC, Calvet CM, et al. ((2010)) A comparative study of posaconazole and benznidazole in the prevention of heart damage and promotion of trypanocidal immune response in a murine model of Chagas disease. Int J Antimicrob Agents 36:: 79--83.
12. Pinazo M-J, Espinosa G, Gállego M, López-Chejade PL, Urbina J, et al. ((2010)) Treatment with posaconazole of a patient with systemic lupus erythematosus and Chagas Disease. Am J Trop Med Hyg 82:: 583--587.
13. Lazardi K, Urbina JA, de Souza W, ((1990)) Ultrastructural alterations induced by two ergosterol biosynthesis inhibitors, ketoconazole and terbinafine, on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi. Antimicrob Agents Chemother 34:: 2097--2105.
14. Doyle PS, Chen C-K, Johnston JB, Hopkins SD, Leung SSF, et al. ((2010)) A nonazole CYP51 inhibitor cures Chagas' Disease in a mouse model of acute infection. Antimicrob Agents Chemother 54:: 2480--2488.
15. Heeres J, Meerpoel L, Lewi P, ((2010)) Conazoles. Molecules 15:: 4129--4188.
16. Kauffman CA, Malani AN, Easley C, Kirkpatrick P, ((2007)) Posaconazole. Nat Rev Drug Discov 6:: 183--184.
17. Katragkou A, Tsikopoulou F, Roilides E, Zaoutis TE, ((2011)) Posaconazole: when and how? The clinician's view. Mycoses 55:: 110--122.
18. Urbina JA, Payares G, Molina J, Sanoja C, Liendo A, et al. ((1996)) Cure of short- and long-term experimental Chagas' disease using D0870. Science 273:: 969--971.
19. Urbina JA, Payares G, Contreras LM, Liendo A, Sanoja C, et al. ((1998)) Antiproliferative effects and mechanism of action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Antimicrob Agents Chemother 42:: 1771--1777.
20. Schenkman JB, Remmer H, Estabrook RW, ((1967)) Spectral studies of drug interaction with hepatic microsomal cytochrome. Mol Pharmacol 3:: 113--123.
21. von Kries JP, Warrier T, Podust LM, ((2010)) Identification of small-molecule scaffolds for P450 inhibitors. Curr Protoc Microbiol 16:: Unit 17.14.
22. Podust LM, von Kries JP, Nasser Eddine A, Kim Y, Yermalitskaya LV, et al. ((2007)) Small molecule scaffolds for CYP51 inhibitors identified by high-throughput screening and defined by x-ray crystallography. Antimicrob Agents Chemother 51:: 3915--3923.
23. Chen C-K, Doyle PS, Yermalitskaya LV, Mackey ZB, Ang KKH, et al. ((2009)) Trypanosoma cruzi CYP51 inhibitor derived from a Mycobacterium tuberculosis screen hit. PLoS Negl Trop Dis 3:: e372.
24. Chen C-K, Leung SSF, Guilbert C, Jacobson MP, McKerrow JH, et al. ((2010)) Structural characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei bound to the antifungal drugs posaconazole and fluconazole. PLoS Negl Trop Dis 4:: e651.
25. Omura T, Sato R, ((1964)) The carbon monoxide-binding pigment of liver microsomes. II. Solubilization, purification, and properties. J Biol Chem 239:: 2379--2385.
26. Ouellet H, Kells PM, Ortiz de Montellano PR, Podust LM, ((2010)) Reverse type I inhibitor of Mycobacterium tuberculosis CYP125A1. Bioorg Med Chem Lett 21:: 332--337.
27. Morrison JF, ((1969)) Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors. Biochim Biophys Acta 185:: 269--286.
28. Engel JC, Doyle PS, Dvorak JA, ((1985)) Trypanosoma cruzi: biological characterization of clones derived from chronic chagasic patients. II. Quantitative analysis of the intracellular cycle. J Protozool 32:: 80--83.
29. Engel JC, Ang KKH, Chen S, Arkin MR, McKerrow JH, et al. ((2010)) Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' Disease. Antimicrob Agents Chemother 54:: 3326--3334.
30. Engel JC, Doyle PS, Hsieh I, McKerrow JH, ((1998)) Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection. J Exp Med 188:: 725--734.
31. McKerrow JH, Doyle PS, Engel JC, Podust LM, Robertson SA, et al. ((2009)) Two approaches to discovering and developing new drugs for Chagas disease. Mem Inst Oswaldo Cruz 104:: 263--269.
32. Hassan M, Brown R, Varma-O'Brien S, Rogers D, ((2006)) Cheminformatics analysis and learning in a data pipelining environment. Mol Divers 10:: 283--299.
33. Rogers D, Hahn M, ((2010)) Extended-Connectivity Fingerprints. J Chem Inf Model 50:: 742--754.
34. Hassan M, Bielawski JP, Hempel JC, Waldman M, ((1996)) Optimization and visualization of molecular diversity of combinatorial libraries. Mol Divers 2:: 64--74.
35. Kaufman L, Rousseeuw P, ((1990)) Finding Groups in Data: An Introduction to Cluster Analysis. Hoboken, New Jersey: John Wiley & Sons.
36. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ, ((2001)) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:: 3--26.
37. Irwin JJ, Shoichet BK, ((2005)) ZINC-a free database of commercially available compounds for virtual screening. J Chem Inf Model 45:: 177--182.
38. Urbina JA, Lazardi K, Aguirre T, Piras MM, Piras R, ((1991)) Antiproliferative effects and mechanism of action of ICI 195,739, a novel bis-triazole derivative, on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi. Antimicrob Agents Chemother 35:: 730--735.
39. Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, et al. ((2007)) Relating protein pharmacology by ligand chemistry. Nat Biotechnol 25:: 197--206.
40. Sakariassen KS, Alberts P, Fontana P, Mann J, Bounameaux H, et al. ((2009)) Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases. Future Cardiology 5:: 479--493.
41. Hardwick JP, ((2008)) Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases. Biochem Pharmacol 75:: 2263--2275.
42. Courtney KD, Taplin ME, ((2012)) The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer. Curr Opin Oncol DOI:10.1097/CCO.0b013e328351059d.
43. Litton JK, Arun BK, Brown PH, Hortobagyi GN, ((2012)) Aromatase inhibitors and breast cancer prevention. Expert Opin Pharmaco 13:: 325--331.
44. Schilling S, Wasternack C, Demuth HU, ((2008)) Glutaminyl cyclases from animals and plants: a case of functionally convergent protein evolution. Biol Chem 389:: 983--991.
45. Oprea TI, ((2002)) Current trends in lead discovery: Are we looking for the appropriate properties? J Comput-Aided Mol Des 16:: 325--334.
46. Lignell A, Lowdin E, Cars O, Chryssanthou E, Sjolin J, ((2011)) Posaconazole in human serum: a greater pharmacodynamic effect than predicted by the non-protein-bound serum concentration. Antimicrob Agents Chemother 55:: 3099--3104.
47. Dolton MJ, Ray JE, Marriott D, McLachlan AJ, ((2012)) Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. Antimicrob Agents Chemother.
48. Campoli P, Al Abdallah Q, Robitaille R, Solis NV, Fielhaber JA, et al. ((2011)) Concentration of antifungal agents within host cell membranes: a new paradigm governing the efficacy of prophylaxis. Antimicrob Agents Chemother 55:: 5732--5739.
49. Urbina JA, ((1999)) Chemotherapy of Chagas' disease: the how and the why. J Mol Med 77:: 332--338.
50. Urbina JA, ((2010)) Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop 115:: 55--68.
51. Nwaka S, Hudson A, ((2006)) Innovative lead discovery strategies for tropical diseases. Nat Rev Drug Discov 5:: 941--955.
52. Gelb MH, Van Voorhis WC, Buckner FS, Yokoyama K, Eastman R, et al. ((2003)) Protein farnesyl and N-myristoyl transferases: piggy-back medicinal chemistry targets for the development of antitrypanosomatid and antimalarial therapeutics. Mol Biochem Parasitol 126:: 155--163.
53. Hucke O, Gelb MH, Verlinde CL, Buckner FS, ((2005)) The protein farnesyltransferase inhibitor Tipifarnib as a new lead for the development of drugs against Chagas disease. J Med Chem 48:: 5415--5418.
54. Chennamaneni NK, Arif J, Buckner FS, Gelb MH, ((2009)) Isoquinoline-based analogs of the cancer drug clinical candidate tipifarnib as anti-Trypanosoma cruzi agents. Bioorg Med Chem Lett 19:: 6582--6584.
55. Kraus JM, Verlinde CL, Karimi M, Lepesheva GI, Gelb MH, et al. ((2009)) Rational modification of a candidate cancer drug for use against Chagas disease. J Med Chem 52:: 1639--1647.
56. Kraus JM, Tatipaka HB, McGuffin SA, Chennamaneni NK, Karimi M, et al. ((2010)) Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery. J Med Chem 53:: 3887--3898.
57. Lepesheva GI, Hargrove TY, Anderson S, Kleshchenko Y, Furtak V, et al. ((2010)) Structural insights into inhibition of sterol 14alpha-demethylase in the human pathogen Trypanosoma cruzi. J Biol Chem 285:: 25582--25590.
58. Mann PA, Parmegiani RM, Wei SQ, Mendrick CA, Li X, et al. ((2003)) Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase. Antimicrob Agents Chemother 47:: 577--581.
59. Mellado E, Garcia-Effron G, Alcazar-Fuoli L, Cuenca-Estrella M, Rodriguez-Tudela JL, ((2004)) Substitutions at methionine 220 in the 14alpha-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrob Agents Chemother 48:: 2747--2750.
60. Rodriguez-Tudela JL, Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, Monzon A, et al. ((2008)) Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob Agents Chemother 52:: 2468--2472.
61. Pinto e Silva AT, Costa-de-Oliveira S, Silva-Dias A, Pina-Vaz C, Rodrigues AG, ((2009)) Dynamics of in vitro acquisition of resistance by Candida parapsilosis to different azoles. FEMS Yeast Res 9:: 626--633.
62. Ali A, Bandaranayake RM, Cai Y, King NM, Kolli M, et al. ((2010)) Molecular basis for drug resistance in HIV-1 protease. Viruses 2:: 2509--2535.
63. Verdonk ML, Hartshorn MJ, ((2004)) Structure-guided fragment screening for lead discovery. Curr Opin Drug Discov Devel 7:: 404--410.